{"id":"egfr-tk-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Rash/acneiform dermatitis"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Interstitial lung disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EGFR-TK inhibitors are small molecules that competitively bind to the ATP-binding pocket of EGFR's intracellular tyrosine kinase domain, preventing autophosphorylation and activation of downstream signaling pathways (such as MAPK and PI3K/AKT). This leads to cell cycle arrest and apoptosis in EGFR-dependent tumors, particularly those with activating EGFR mutations.","oneSentence":"This drug inhibits tyrosine kinase activity of the epidermal growth factor receptor (EGFR), blocking downstream signaling that drives cancer cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:44.375Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR mutations (likely primary indication based on drug class)"}]},"trialDetails":[{"nctId":"NCT06305754","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-06-11","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":520},{"nctId":"NCT02503722","phase":"PHASE1","title":"Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-23","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7","enrollment":36},{"nctId":"NCT02496663","phase":"PHASE1","title":"Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-11","conditions":"Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":138},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT07326566","phase":"PHASE2","title":"Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII","status":"RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2026-04","conditions":"Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM","enrollment":162},{"nctId":"NCT07185997","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations","status":"RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2025-12-17","conditions":"Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer","enrollment":480},{"nctId":"NCT07100080","phase":"PHASE2, PHASE3","title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-11-05","conditions":"Non-Small Cell Lung Cancer","enrollment":596},{"nctId":"NCT06671379","phase":"PHASE3","title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-11-29","conditions":"Non-small Cell Lung Cancer","enrollment":498},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT06775743","phase":"PHASE2","title":"ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-01-15","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer","enrollment":53},{"nctId":"NCT06905197","phase":"PHASE1","title":"A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-05-13","conditions":"Non Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT07217028","phase":"PHASE1","title":"Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2026-04","conditions":"SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma","enrollment":60},{"nctId":"NCT04290546","phase":"PHASE1","title":"CIML NK Cell in Head & Neck Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-07-20","conditions":"Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":11},{"nctId":"NCT02716116","phase":"PHASE1, PHASE2","title":"A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2016-06-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":334},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT04868877","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merus B.V.","startDate":"2021-04-28","conditions":"Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma","enrollment":194},{"nctId":"NCT04485013","phase":"PHASE1","title":"TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers","status":"RECRUITING","sponsor":"Tizona Therapeutics, Inc","startDate":"2020-07-14","conditions":"Cancer","enrollment":240},{"nctId":"NCT07416058","phase":"PHASE2","title":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2026-01-31","conditions":"Lung Adenocarcinoma","enrollment":61},{"nctId":"NCT05358249","phase":"PHASE1, PHASE2","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-10-24","conditions":"KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung","enrollment":74},{"nctId":"NCT06501989","phase":"PHASE2","title":"Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"Inova Health Care Services","startDate":"2025-09-19","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT06830863","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity","status":"RECRUITING","sponsor":"Azitra Inc.","startDate":"2025-08-25","conditions":"EGFR Inhibitor-associated Rash","enrollment":32},{"nctId":"NCT07229339","phase":"PHASE2","title":"Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2027-06-01","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":16},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT03040973","phase":"PHASE2","title":"Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-23","conditions":"Advanced Solid Tumors Which Are cMET-dependent","enrollment":29},{"nctId":"NCT03974022","phase":"PHASE1, PHASE2","title":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2019-07-09","conditions":"Non-Small Cell Lung Cancer","enrollment":315},{"nctId":"NCT05827614","phase":"PHASE1","title":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boundless Bio, Inc.","startDate":"2023-03-24","conditions":"Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma","enrollment":85},{"nctId":"NCT03392246","phase":"PHASE2","title":"A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-01-31","conditions":"Non-small Cell Lung Cancer","enrollment":25},{"nctId":"NCT04486833","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib","status":"RECRUITING","sponsor":"Genprex, Inc.","startDate":"2021-09-03","conditions":"Carcinoma, Non-Small Cell Lung","enrollment":158},{"nctId":"NCT06302621","phase":"PHASE1","title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-04-17","conditions":"Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor","enrollment":70},{"nctId":"NCT07094893","phase":"PHASE4","title":"Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2026-04-15","conditions":"Colorectal Cancer","enrollment":280},{"nctId":"NCT07338396","phase":"","title":"A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2026-01","conditions":"Non Small Cell Lung Cancer NSCLC","enrollment":3000},{"nctId":"NCT05002270","phase":"PHASE1, PHASE2","title":"JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation","status":"COMPLETED","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2021-09-03","conditions":"Advanced Solid Tumor, NSCLC, CRC","enrollment":29},{"nctId":"NCT07318805","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-16","conditions":"Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer","enrollment":260},{"nctId":"NCT03983993","phase":"PHASE2","title":"Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-10-15","conditions":"Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Microsatellite Stable","enrollment":26},{"nctId":"NCT07315113","phase":"PHASE1","title":"Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nuvectis Pharma, Inc.","startDate":"2025-12-18","conditions":"EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients","enrollment":18},{"nctId":"NCT06813365","phase":"PHASE1","title":"Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2024-06-12","conditions":"Nonsmall-cell Lung Cancer","enrollment":190},{"nctId":"NCT07079475","phase":"PHASE1, PHASE2","title":"Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-07-31","conditions":"Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT07285148","phase":"PHASE1, PHASE2","title":"A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Beijing Pearl Biotechnology Limited Liability Company","startDate":"2026-06","conditions":"Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer","enrollment":253},{"nctId":"NCT05256290","phase":"PHASE1, PHASE2","title":"Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"Black Diamond Therapeutics, Inc.","startDate":"2022-03-31","conditions":"Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma","enrollment":200},{"nctId":"NCT07267247","phase":"","title":"Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Taichung Veterans General Hospital","startDate":"2022-06-01","conditions":"Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung), Drug-Related Side Effects and Adverse Reactions (MeSH Term), Egfr Tyrosine Kinase Inhibitor","enrollment":100},{"nctId":"NCT06662760","phase":"PHASE1","title":"Clinical Trial of TQB3002 in Patients With Advanced Cancers","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-12-09","conditions":"Advanced Cancer","enrollment":150},{"nctId":"NCT07089641","phase":"PHASE1","title":"ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-07-28","conditions":"IDH Wildtype Glioblastoma, Recurrent Astrocytoma, IDH Wildtype Recurrent Glioblastoma","enrollment":10},{"nctId":"NCT05456256","phase":"PHASE2","title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Lantern Pharma Inc.","startDate":"2023-03-01","conditions":"Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung","enrollment":90},{"nctId":"NCT03122717","phase":"PHASE1, PHASE2","title":"Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-05-09","conditions":"Non-Small Cell Lung Cancer","enrollment":48},{"nctId":"NCT03586453","phase":"PHASE2","title":"Osimertinib In EGFR Mutant Lung Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-08-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT03471364","phase":"EARLY_PHASE1","title":"Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-09-25","conditions":"Malignant Neoplasm","enrollment":58},{"nctId":"NCT05393466","phase":"PHASE1, PHASE2","title":"BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Xcovery Holdings, Inc.","startDate":"2026-07-01","conditions":"Non-small Cell Lung Carcinoma","enrollment":30},{"nctId":"NCT07141381","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755","status":"RECRUITING","sponsor":"Voronoi, Inc","startDate":"2025-08-27","conditions":"Healthy","enrollment":24},{"nctId":"NCT06567015","phase":"PHASE1, PHASE2","title":"Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2024-09-17","conditions":"Non-small Cell Lung Cancer (NSCLC)","enrollment":171},{"nctId":"NCT06020066","phase":"PHASE2","title":"SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-08-10","conditions":"Brain Metastases, Non-small Cell Lung Cancer","enrollment":202},{"nctId":"NCT05107674","phase":"PHASE1","title":"A Study of NX-1607 in Adults With Advanced Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer","enrollment":345},{"nctId":"NCT07105592","phase":"PHASE1, PHASE2","title":"A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-13","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT05639933","phase":"PHASE2","title":"Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors","status":"RECRUITING","sponsor":"Hoth Therapeutics, Inc.","startDate":"2023-07-19","conditions":"Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia","enrollment":152},{"nctId":"NCT03175224","phase":"PHASE2","title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","status":"RECRUITING","sponsor":"Apollomics Inc.","startDate":"2017-09-27","conditions":"Solid Tumors, Advanced Cancer, Renal Cancer","enrollment":497},{"nctId":"NCT02191891","phase":"PHASE1","title":"Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":32},{"nctId":"NCT06947811","phase":"PHASE1, PHASE2","title":"A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-09","conditions":"EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor","enrollment":71},{"nctId":"NCT06992739","phase":"PHASE2","title":"Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-06","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression","enrollment":49},{"nctId":"NCT01393821","phase":"NA","title":"Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-23","conditions":"Dermatologic Complications, Malignant Neoplasm, Pain","enrollment":27},{"nctId":"NCT06955325","phase":"PHASE3","title":"Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-05","conditions":"Non-Small Cell Lung Cancer","enrollment":270},{"nctId":"NCT04075396","phase":"PHASE1, PHASE2","title":"A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-10-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":29},{"nctId":"NCT05630989","phase":"","title":"A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy","status":"RECRUITING","sponsor":"Mandana Kamgar, MD","startDate":"2023-02-07","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":80},{"nctId":"NCT03428958","phase":"PHASE1, PHASE2","title":"A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment","status":"COMPLETED","sponsor":"NuCana plc","startDate":"2018-10-05","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":111},{"nctId":"NCT06046495","phase":"PHASE1","title":"A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2024-07-08","conditions":"Non-Small Cell Lung Cancer","enrollment":81},{"nctId":"NCT01853826","phase":"PHASE3","title":"An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07-17","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":481},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT05241873","phase":"PHASE1","title":"(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations","status":"TERMINATED","sponsor":"Blueprint Medicines Corporation","startDate":"2022-03-04","conditions":"Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms","enrollment":103},{"nctId":"NCT06818058","phase":"PHASE2","title":"TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis","status":"RECRUITING","sponsor":"Tarian Pharma","startDate":"2025-01-20","conditions":"EGFR Inhibitor-associated Rash","enrollment":60},{"nctId":"NCT05338970","phase":"PHASE3","title":"HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2022-07-08","conditions":"Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion","enrollment":586},{"nctId":"NCT06071013","phase":"PHASE1, PHASE2","title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","status":"RECRUITING","sponsor":"China Medical University Hospital","startDate":"2024-02-23","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation","enrollment":20},{"nctId":"NCT04824079","phase":"PHASE2","title":"Keynatinib in Treated Patients With NSCLC and Brain Metastases","status":"COMPLETED","sponsor":"Medolution Ltd.","startDate":"2020-10-21","conditions":"Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases","enrollment":16},{"nctId":"NCT06759857","phase":"PHASE3","title":"FHND9041 Versus Afatinib for Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.","startDate":"2021-08-01","conditions":"Non Small Cell Lung Cancer","enrollment":350},{"nctId":"NCT02495233","phase":"PHASE1, PHASE2","title":"A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2015-09-08","conditions":"Non-Small-Cell Lung Cancer","enrollment":10},{"nctId":"NCT06526923","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)","status":"RECRUITING","sponsor":"Spirovant Sciences, Inc.","startDate":"2024-09-16","conditions":"Cystic Fibrosis","enrollment":15},{"nctId":"NCT02500927","phase":"PHASE2","title":"A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2015-06-25","conditions":"EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations","enrollment":31},{"nctId":"NCT02192697","phase":"PHASE1, PHASE2","title":"An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations","status":"TERMINATED","sponsor":"Astellas Pharma Inc","startDate":"2014-01-23","conditions":"Non-small Cell Lung Cancer","enrollment":124},{"nctId":"NCT02113813","phase":"PHASE1","title":"A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-04-09","conditions":"Non-Small-Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor Mutations","enrollment":133},{"nctId":"NCT04800822","phase":"PHASE1","title":"PF-07284892 in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Pfizer","startDate":"2021-03-17","conditions":"Solid Tumor","enrollment":53},{"nctId":"NCT03239340","phase":"PHASE2","title":"A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-30","conditions":"EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":154},{"nctId":"NCT06585059","phase":"PHASE1","title":"Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2024-09","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":20},{"nctId":"NCT05007938","phase":"PHASE2","title":"Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Betta Pharmaceuticals Co., Ltd.","startDate":"2021-08-12","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT00788957","phase":"PHASE1, PHASE2","title":"Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"NantBioScience, Inc.","startDate":"2008-10-27","conditions":"Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer","enrollment":177},{"nctId":"NCT06517953","phase":"PHASE2","title":"Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-17","conditions":"Non-small Cell Lung Cancer Metastatic, EGFR G719X, EGFR L861Q","enrollment":23},{"nctId":"NCT06509997","phase":"PHASE2","title":"A Phase II Study of Anti-EGFR Antibody-drug Conjugate (ADC) Combine With CDK4/6 Inhibitors Posterior Line in the Treatment of Recurrent/Metastatic CDKN2A Gene Variant Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Lei Liu","startDate":"2024-08-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT00254384","phase":"PHASE1","title":"Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-10-05","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":50},{"nctId":"NCT06486142","phase":"PHASE3","title":"EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","status":"RECRUITING","sponsor":"Region Skane","startDate":"2022-09-21","conditions":"Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT04222335","phase":"NA","title":"Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2021-03-26","conditions":"Lung Cancer, Nonsmall Cell","enrollment":80},{"nctId":"NCT06032936","phase":"PHASE1","title":"BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations","status":"TERMINATED","sponsor":"LianBio LLC","startDate":"2023-07-27","conditions":"NSCLC","enrollment":4},{"nctId":"NCT02759835","phase":"PHASE2","title":"Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-13","conditions":"Lung Adenocarcinoma, Lung Neoplasms","enrollment":37},{"nctId":"NCT06109558","phase":"PHASE1, PHASE2","title":"The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC","status":"RECRUITING","sponsor":"Hunan Province Tumor Hospital","startDate":"2023-12-31","conditions":"Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification","enrollment":120},{"nctId":"NCT05559645","phase":"NA","title":"Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-11-18","conditions":"Non Small Cell Lung Cancer","enrollment":180},{"nctId":"NCT06411093","phase":"NA","title":"Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2023-03-02","conditions":"Paronychia, Epidermal Growth Factor Receptor Inhibitor","enrollment":24},{"nctId":"NCT00657098","phase":"","title":"Side Effects of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) Directed Therapy","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2008-03","conditions":"Metastatic Malignancies","enrollment":73},{"nctId":"NCT04147351","phase":"PHASE2","title":"A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-04-10","conditions":"NSCLC Stage IIIB~IV","enrollment":22},{"nctId":"NCT05378360","phase":"PHASE2","title":"DWP708 for Treating Epidermal Growth Factor Receptor Inhibitor Related Skin Toxicities","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-05-02","conditions":"Rash Acneiform","enrollment":96},{"nctId":"NCT06334757","phase":"PHASE2","title":"Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2023-05-08","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":46},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02467569","phase":"PHASE1","title":"Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer","status":"TERMINATED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2015-07-03","conditions":"Neoplasms，Non-Small Cell Lung Cancer","enrollment":10},{"nctId":"NCT02476539","phase":"PHASE1","title":"Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2015-10-14","conditions":"HER2 Positive Breast Cancer","enrollment":28},{"nctId":"NCT03516214","phase":"PHASE1","title":"EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2018-04-25","conditions":"Bronchial Neoplasms","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"INTERSTITIAL LUNG DISEASE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["gefitinib","Recombinant human endostatin"],"phase":"phase_3","status":"active","brandName":"EGFR-TK Inhibitor","genericName":"EGFR-TK Inhibitor","companyName":"Xinqiao Hospital of Chongqing","companyId":"xinqiao-hospital-of-chongqing","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EGFR-TK Inhibitors are small molecule drugs that target the epidermal growth factor receptor tyrosine kinase, and they are primarily used to treat Non-Small Cell Lung Cancer, particularly in patients with EGFR mutations. These inhibitors have been studied in clinical trials for various indications, including Non-Small Cell Lung Cancer with EGFR mutation and brain metastases.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-04-26T00:00:00.000Z","mah":"ACTAVIS LABS FL INC","brand_name_local":"GEFITINIB","application_number":"ANDA208913"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-05-31T00:00:00.000Z","mah":"NATCO","brand_name_local":"GEFITINIB","application_number":"ANDA212827"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-05-16T00:00:00.000Z","mah":"CIPLA","brand_name_local":"GEFITINIB","application_number":"ANDA211826"}],"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}